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ABSTRACT OF THE THESIS
THE OSCILLATORY SHEAR INDEX: QUANTIFICATIONS FOR VALVE TISSUE
ENGINEERING AND A NOVEL INTERPRETATION FOR CALCIFICATION
by
Alexander T. Williams
Florida International University, 2018
Miami, Florida
Professor Sharan Ramaswamy, Major Professor
Heart valve tissue engineering (HVTE) stands as a potential intervention that could
reduce the prevalence of congenital heart valve disease in juvenile patients. Prior studies
in our laboratory have utilized mechanobiological testing to quantify the forces involved
in the development of heart valve tissue, utilizing a Flow-Stretch-Flexure (FSF)
bioreactor to condition bone marrow stem cells (BMSCs)-derived valve tissue.
Simulations have demonstrated that certain sets of flow conditions can introduce specific
levels of oscillatory shear stress (OSS)-induced stimuli, augmenting the growth of
engineered valves as well as influencing collagen formation, extracellular matrix (ECM)
composition and gene expression. The computational findings discussed in this thesis
outline the methods in which flow conditions, when physiologically relevant, induce
specific oscillatory shear stresses which could not only lead to an optimized valve tissue
phenotype (at 0.18≤ OSI≤ 0.23), but could identify native valve tissue remodeling
indicative of aortic valve disease.
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1. INTRODUCTION
1.1 Problem Statement:
Heart valve disease remains a prevalent concern in patients with cardiovascular
disease and pediatric patients with congenital heart defects. Several potential
interventions can be applied to these patients to mitigate the effects of this condition,
one of which involves the application of engineered heart valves (EHVs)[1, 2]. For this
modality, the environment necessary for the appropriate development of engineered
valve tissue would require a specific set of flow conditions to be met. These flow
condition regimes have the potential to induce appreciable development and gene
expression of heart valve tissue [4, 2, 3, 5], with physiological flow conditions
speculated to significantly enhance EHV phenotype. Recapitulating the biological
circumstances necessary for conditioning EHVs would then require an understanding of
the mechanobiological forces crucial to EHV fabrication. Genes, such as klf2a and cd31,
induce favorable maturation in vascular endothelial cells (VECs), which aid in the
activation of regenerative processes of heart valve tissue. These genes also induce
viability in bone marrow stem cells (BMSCs), which were found to be imperative in the
fabrication of engineered valves. Such genes were found to be present when certain flow
parameters, such as shear stress, occurred at the tissue level [6, 7].
These flow patterns have also been shown to influence valve blood flow mechanics in
native valve tissue. From a hemodynamical standpoint, abnormal flow physics have
been shown to progress aortic valve disease by influencing the accumulation of calcified
plaque deposits along valve leaflets [9, 8, 2, 10]. Further studies have shown that aortic
valve remodeling is affected by an abnormal flow regime, such as was found with wall
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shear stress, which could be an initiator in the process of valve calcification [11]. Based
on these implications, we hypothesize that the oscillatory flow physics that exist at the
tissue level would not only indicate gene expression that corresponds to a potential
optimization in EHV formation and phenotype, but could also act as an indicator for the
remodeling of the tri-leaflet valve systems in terms of valve calcification.
1.2 Current Barriers:
Extensive research in the fields of biomechanics realize EHV development across a
gene-tissue hierarchy. In our lab, the research carried out has implemented a simulated
Flow-Stretch-Flexure (FSF) bioreactor (Fig. 1) to identify the conditions that moderate
the fluid flow parameters involved in engineering valve tissue. Computational studies
have shown that there is a
correlation between oscillatory
shear stresses and valve
development, including
appreciable collagen formation

Fig.1: (a) FSF Bioreactor Chamber schematic [25] used to
design (b) a simulated bioreactor model modelled on
ANSYS® CFX

and valvular phenotype [5, 12, 13]. These findings suggest that there should then be a
particular range of oscillatory shear stresses (OSS) that could correspond not only to
engineered valve tissue augmentation, but also to the expression of genes that sustain the
architecture and functionality of EHVs. However, the distinct conditions that would
express these levels of OSS have not yet been determined. Furthermore, there is little
evidence on whether such conditions would impose similar levels of OSS across an
appropriate physiologically relevant model, i.e. healthy aortic valve leaflets, or if such
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conditions derive such OSS levels specifically across the geometric configuration of the
poly(l-lactic acid) / poly(l-glutamic acid) (PLLA/PLGA) scaffold-based FSF bioreactor
environment.
Retrospectively, since fluid flow is crucial in the facilitation of OSS [14, 6], a
previous report [12] suggests that a physiologically relevant, vessel-specific flow regime
could produce a range of OSS, summarized as an oscillatory shear index (OSI) between
0 and 0.5 (Eq. 1), that is theorized to optimize valvular phenotypic characteristics and
gene expression specific to EHVs [12]. Considering the ramifications of this study, the
FSF bioreactor geometry was re𝑇

deployed to simulate physiological
conditions for identifying flow

𝑂𝑆𝐼 = 0.5 ∙ (1 −

|∫0 𝑊𝑆𝑆 𝑑𝑡|
𝑇

∫0 |𝑊𝑆𝑆| 𝑑𝑡

)

parameters across a typical
Equation 1: Oscillatory Shear Index

bioreactor environment.

There are several flow parameters that could influence the development of valve
disease in native tri-leaflet valves [9, 2, 15, 16, 17 18, 10]. However, few studies have
looked at how the remodeling of the valvular ECM environment could be affected by
OSS-induced stimuli and whether this remodeling could correlate to adverse effects, i.e.
calcified plaque deposits, which lead to valve disease. Subsequently, physiological
conditions were prescribed to a healthy heart valve conduit, undergoing mid-diastole, to
correlate the flow parameters along the scaffolds to those involved with the geometry of
the valve leaflets when exposed to similar conditions. Additional simulations were run,
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adding calcified deposits to the heart valve geometry to identify if there were any
notable variations in the OSI distribution of a diseased valve model geometry.
1.3. Specific Aims:
The hypothesis was tested using the following specific aims:
Specific Aim 1: Simulating physiologically relevant flow conditions across a 3Dcomputational tissue-level environment, and demarcating flow physics across the
BMSC-layered scaffolds of the model.
Specific Aim 2: Modelling physiologically relevant flow conditions across heart valve
models, both healthy and calcified, and distinguishing the flow parameters specific to
both normal valve hemodynamics and region-defined valve calcification.
1.4.

Methodologies:

To efficiently carry out and run the simulated experiments, an Intel Xeon® X5550
central processing unit with dual processors (2.66 and 2.667 GHz) was employed due to
its processing power rendering it capable of maintaining multiple simulations. The study
also used a Windows® 7 64-bit operating system which met with the software
requirements necessary from the appropriate simulation software and the graphics that
coincide with the results.
The tissue-based simulations, executed through ANSYS Workbench®2016 (ANSYS
Inc., Canonsburg, PA) used a set of physiologically relevant, vessel-specific velocity
profiles (fig.2, 3, 4) prescribed to the inlet of the given geometry. The tissue-based
simulations used the fluid parameters of cell culture basal media, in which the simulated
fluid was Newtonian, produced laminar flow, and had both a density of 1.01 g/cm3 and
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a viscosity of 1.27 cP. For each simulation run, transient data needed to reach an
appropriate level of accuracy during the solution phase of each computation, which
required the convergence criteria to be set to 1 x 10-9 and each given time step, of the
respective timeframe for each profile, to go through 50 iterations to ensure result
precision. Computational properties of tissue-level studies, such as the geometry or the
fluid properties, were validated with previous simulated pulsatile studies.
For the valve-based computational geometries, 3D reconstructions of both a healthy
valve-aortic root (AVAR) anatomy and a diseased AVAR anatomy were modelled
within SolidWorks ®2015a. Each model was then separately imported into ANSYS
Workbench®2016, similar to the tissue-based simulations, using the aortic-specific
velocity profile (fig. 3) as an inlet boundary condition. The simulations used the fluid
parameters of blood, a non-Newtonian simulated fluid with a density of 1.06 g/cm3 and
a viscosity of 3.5 cP. The boundary conditions were employed into the model with an
80 mm Hg-pressure profile prescribed to the outlet and no-slip boundary conditions
applied to the overall structure of the model. The valve-based studies were validated by
computing a 120 mm Hg pressure reading at the inlet when utilizing pulsatile conditions
across the healthy valve.
After collecting OSI and time-averaged wall shear stress (TAWSS) data from the
tissue-based simulations, the quantifications were compared to data originating from
shear stress boundary conditions used for shear stress experiments, which were executed
within a Bioflux 1000 system (Fluxion Biosciences, South San Francisco, CA) for
BMSCs. Associations between the given parameters were able to determine whether
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there was a link between the acquired computed data and the genes expressed during the
shear stress experiments.
For the flow quantifications found within this study, the mean and standard error of
the mean for both cases were given for each parameter used. Statistical differences
between the simulated data and the experimental data were confirmed using ANOVA
tests (p<0.05).
2. LITERATURE REVIEW
2.1. Heart Valve Disease
Heart valve disease has been increasing in incidence in the United States with an
estimated 1.5 million citizens affected [19]. Some of the symptoms of heart valve
disease include regurgitation, which involves blood flowing back into the ventricle
during diastole, and stenosis, which involve occlusions of the valve orifice most
prominently from the stiffening and thickening of the valves, which can be due to
calcification. The most common cases of aortic valve stenosis (AVS) occur as calcific
aortic stenoses, which can be developed with age, and congenital bicuspid aortic
stenoses, diagnosed at birth [15, 18].
AVS, once considered an age-related degenerative condition resulting in the formation
of calcium deposits in heart valves, has recently been shown to be involved in an
intricate set of processes similar to atherosclerosis. These processes have been
demonstrated to damage the valvular endothelial layer due to an increase in mechanical
stresses, thought to be an initializing event for developing AVS [20, 18]. The flow of
blood through the aortic valve accounts for these fluid-induced mechanical forces, such
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as the shear stress across the valves, leading to abnormalities within the cellular
architecture of both the fibrotic and ventricularis sides of aortic valves, given any
quantifiable deviations of these fluid-induced forces.
VECs, undergoing physiological shear stress values, respond by expressing antiinflammatory genes; however, when they are exposed to abnormal fluid flow shear
stress, inflammatory mediators were activated. Studies have also shown the activation
of calcification-related genes after VECs have been exposed to abnormal shear stresses.
[11, 21]. Though it has been shown that discrepancies in mechanotransductive forces
and tissue hemodynamics could lead to endothelial damage, these flow field mechanics,
given normal, healthy circumstances, substantially maintain the environment of
engineered valve tissue [ 2, 10 ,18-21].
2.2. Heart Valve Replacement and Repair Procedures
2.2.1. Replacement
Heart valve prosthetics have been recognized as a suitable method to replace diseased
heart valves. Early heart valve prosthetics during early valve prosthetic implantation
used mechanical heart valves (MHVs). MHVs used in clinical trials had several different
variants, including the ball-and-cage mechanical valve, the rotating disk valve and
bileaflet trileaflet mechanical valves. However, MHVs were associated with irregular
hemodynamics, such as high velocity backflow jets and high shear stresses across hinges
of the valves, causing hemolytic dysfunction, and requiring patients to take life-long
anticoagulation medications. [3]
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In such cases, bioprosthetic heart valves (BHVs) were developed to better acclimate
with the environment of the aorta due to its integration of native tissue from animals
(xenografts), human donors (homografts), or from the patient's body (autografts). The
main advantage of bioprosthetic heart valves was that patients would not be required to
take life-long anticoagulants. However, the risk for BHV replacements came from the
structural valve deterioration that occurred from the narrow durability and stability of
BHVs, which would then increase the chance for reoperation, particularly for pediatric
patients [3, 23].
2.2.2. Repair
Valvular surgery is the other intervention which could be used to treat damaged,
diseased or calcified heart valves, typically involving open heart surgery. Several
techniques have been developed for the repair of aortic valves, including the Ross
procedure, which involves aortic repair utilizing pulmonary valve tissue, and minimal
access aortic valve surgery through which sutureless valves could potentially improve.
It is the more ideal choice for severe regurgitation due to valve prolapse, though aortic
root remodeling could also ultimately be necessary for this type of repair. Foregoing
valve replacement with repair could sometimes lead to a postoperative revision, though
the reoperation rate usually occurs between 2-3%, not looking beyond the results that
occur 10 years post-operation. [24]
2.3. Tissue Engineering and Regenerative Methods for Heart Valves
2.3.1. Motivation
An appropriate potential alternative for replacement of both mechanical and
bioprosthetic heart valves would involve the use of regenerative approaches to construct
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tissue engineered heart valves (TEHVs). TEHVs are also associated with a more native
set of hemodynamics in comparison to mechanical valves, while also having a lower
potential for reoperation in comparison to bioprosthetic heart valves. Additionally,
unlike both valve replacement modalities, TEHVs not only have a more natural blood
flow regime due to their natural structure, but they have the capability to grow with the
patient, making them suitable for pediatric patients [4, 1, 25].
2.3.2. Challenges
There are several pitfalls that need to be addressed involving the construction of
TEHVs, and consequently restricting their use within the clinic. TEHVs, though
biocompatible, have been shown to undergo complications at the cellular level, in which
interstitial and endothelial cells have limited communication between the extracellular
matrix. Additionally, TEHVs are also subject to flow physics used for conditioning in
controlled environments (i.e., bioreactors) that can vary to the physiological blood flow
physics associated with native valves [4, 3]. Particularly with decellularized TEHVs,
there is also the threat of valvular deterioration that could be caused from inflammatory
rejection [4].
2.3.3. Literature Review of the Field
There have been several approaches taken for the scaffolding and succeeding
development of TEHVs, such as in the study by Konertz et al .[26], which involved
implanting a decellularized porcine aortic valve xenograft into several patients (age
median: 46 years) throughout a two-year timeframe, with the typical recellularization
timespan ranging within four months. The results of the study revealed that the valves
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demonstrated similar characteristics to native healthy valves, particularly due to
sustaining low, consistent transvalvular gradients [26].
Zhou et al. [27] performed polyethylene glycol (PEG)-ylation of decellularized aortic
porcine valves. Mechanical testing revealed that there was a significant increase in the
tensile strength of the aortic valve tissue. The study also looked into using branched
PEG to facilitate the conjugation of bioactive agents, such as vascular endothelial
growth factor (VEGF), onto the aortic valve. Human umbilical vein endothelial cells
(HUVECs) were found to grow appreciably on the tissue when conjugated with VEGF
and glycine-arginine-glycine-aspartate-serine-proline-cysteine (GRGDSPC) peptides
after PEG-ylation.
Schmidt et al. [31] developed a method for minimally invasive surgery of TEHVs
using bioreactor technology and adult stem cells. The trileaflet valves were integrated
onto self-expanding stents and implanted into sheep. In vivo functionality and
composition analyses revealed newly formed valve tissue with the extracellular matrix,
producing higher levels of collagen and glycosaminoglycans than typically found in
native tissue. A similar study was done by Weber et al [28], in which marrow stromalcell-based, autologous TEHVs were fabricated. Then, using Nitinol-based stents, these
TEHVs were implanted into nonhuman primates as pulmonary valves, with composition
and biomechanical analyses demonstrating that the biodegradable scaffold matrix was
being replaced with endothelialized, layered, living tissue.
Syedain et al. [29] applied an off-the-shelf engineered valve within sheep, which
resulted in endothelialization, colonization of interstitial-like cells within the engineered
matrix, new extracellular deposits, such as elastin, retained functionality, and increased
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tissue remodeling 24 weeks after implantation with no calcification. The structural
integrity was also deemed satisfactory according to the number of fatigue cycles the
valve overcame within the time span (17 million cycles).
Engelmeyer et al.[14] created a Flow-Stretch-Flexure (FSF) bioreactor using
mechanical stretching and bending of rectangular, nonwoven 50:50 blend poly (glycolic
acid) (PGA) and poly(l-lactic acid) (PLLA) scaffolds to condition and optimize the
development of bone marrow-derived mesenchymal stem cell (BMSC)-derived TEHVs.
Using two mechanical stimuli physiologically relevant to heart valves, the cyclic flexure
rate of the samples coupled with a laminar flow regime [Flex-Flow], the results of this
study reported high levels of tissue formation, collagen content and effective stiffness
similar to that of smooth muscle cell (SMC)-seeded scaffolds.
Ramaswamy et al [25] subsequently tested the validity of using physiological flow,
stretch and flexure by developing a novel FSF bioreactor for BMSC-derived TEHVs. As
opposed to the study, which looked at the effects of Flex-Flow conditions in optimizing
engineered valve growth, the study by Ramaswamy et al. utilized physiologically
relevant shear stress ranges (5-6 dynes/cm2), leading to higher levels of collagen content
compared to the levels found in Engelmeyer et al., which induced lower, subphysiological shear stress ranges. Furthermore, computational analyses done by Salinas
et al. [6] and Salinas and Ramaswamy [6] identified the flow-mediated mechanics that
took place within the confines of an FSF bioreactor environment. Specifically, fluidinduced oscillatory shear stresses were found to be substantial in the conditioning of
TEHVs.
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2.4. Computational Fluid Dynamics (CFD) and Heart Valve Tissue Engineering
2.4.1. CFD and Heart Valves
Tissue-based computational

𝜕𝑢

a. 𝜌 (𝜕𝑥 + 𝑢 ∙ ∇𝑢) = −∇ ∙ 𝑃 + 𝜌𝑔 + 𝜇 ∙ ∇2 𝑢

analysis, employing the NavierStokes Equations for continuity and
momentum (Eq. 2), has been

b. ∇𝜌 = 0
Equation 2: The Navier Stokes equation represented
by the momentum equation (a) and the continuity
equation (b)

utilized in studies involved with determining the flow physics and mechanical forces
that occur across heart valves. Such analyses have also been applied within other
domains in which valvular tissue is grown and conditioned (i.e., bioreactors). Previous
computational studies have shown that native hemodynamics have certain levels of
shear stresses that are imposed on aortic valve tissue, particularly at a range of 0 to 3.49
dynes/cm2 [30].
2.4.2. Previous Studies in Our Laboratories
2.4.2.1. Flow systems
2.4.2.1.1. Flow-Stretch-Flexure Bioreactor
We have utilized an FSF bioreactor, which seeds human bone marrow stem cells across
scaffolds that undergo certain degrees of flexure and bending, along with supplying a
flow regime across the bioreactor chambers, to provide the mechanical forces necessary
to sustain and even enhance the development of heart valve tissue. With a need to
understand and control the flow physics that impart these mechanical forces across
scaffolds to optimize the quality, phenotype, and growth of engineered heart valves,
employing computational modelling and analysis of the flow conditions, including
ANSYS Workbench ®2016 and Tecplot 360 EX ®2016, provide a sufficient segue to
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resolve this matter. In regard to the mechanical forces that are analyzed within these
studies, principally, we have found that OSS, which oscillate due to the fluctuating of
flow back and forth, can supplement the development of valvular tissue. Our laboratory
has looked at the different sets of flow conditions within the bioreactor geometry,
retaining certain values of oscillatory shear stresses, summarized as OSI, which range
from 0, indicating no oscillating shear patterns, to 0.5, indicating high levels of
oscillatory shear stresses.
2.4.2.1.2. Shear Stress Cell Assay System (Bioflux)
Studies within our lab have used the Bioflux 200 system to condition individual
cells, or groups of cells, by using shear stress profiles to recapitulate multiple conditions
before analyzing the cells’ behavior, gene expression patterns, and morphology. Shear
stress plates previously used have had an applicable shear stress range of 0-20
dynes/cm2.
2.4.3. Steady Flow
Steady-state flow conditions set different cases where the scaffolds were flexed at
varying conformations. When utilized within simulations, results revealed that there was
little to no oscillatory flow (OSI=0) across the tissue specimens when the scaffold was at
constantly straight configurations [6]. Shear stress averages were found to be 1.98
dynes/cm2 at the inner walls, and 2.43 dynes/cm2 at the outer walls [5].
2.4.4. Cyclic Flexure and Steady Flow (Flex-Flow)
Flex-Flow conditions used a steady-state flow regime coupled with cyclic flexing of
the samples at the physiologically relevant frequency of 1 Hz. Results demonstrate that
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the OSI=0.11 at the inner walls of the samples and OSI=0.09 at the outer walls averaged
out to an OSI=0.10. Shear stress averages were found to be 2.91 dynes/cm2 at the inner
walls and 4.73 dynes/cm2 at the outer walls. Use of Flex-Flow showed improved
collagenous formation and optimized expression of genes involved with valvular
development such as Klf-2a and Cdz-1 [5].
2.4.5. Non-Physiological Pulsatile Flow (NPFF)
A square-wave, non-physiological flow regime was prescribed to the inlet of the
bioreactor system. When utilized within simulations, results revealed that there was high
oscillatory flow with an OSI=0.45 at the inner walls and an OSI=0.29 at the outer walls
averaged out to OSI=0.37. Shear stress averages were shown to be 1.5 dynes/cm2 at the
inner walls and 1.2 dynes/cm2 at the outer walls. When used in experiments, NPFF
conditions had similar rates of collagenous development and expression of Cdz-1
compared to the Flex-Flow case, but sustained a statistically significant decrease in the
expression of Klf-2a [12].
3. SPECIFIC AIM 1
Young patients born with critical congenital valve diseases are faced with a grim
prognosis. Prosthetic valves, while a mature technology, do not cater to the small size of
these patients, nor can they enable somatic growth. Towards the development of
functional tissue engineered heart valves (TEHVs) several protocols have been
investigated in an effort to optimize physical, mechanical, and biochemical properties [2,
22, 31]. Regardless of the specific approaches, gene, cellular, and tissue-level responses
of the TEHV are intimately tied to the mechanical environment native to the
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cardiovascular system [2, 23, 32, 12]. Recently, the directionality of fluid-induced shear
stress, i.e., oscillatory shear stresses, have been shown to be essential in heart valve
tissue development including cellular proliferation, extracellular matrix (ECM)
production, and the overall preservation of the valvular phenotype [33–35]. In an in
vivo model, Vermot et al established a link between OSS and its direct regulatory role
on the critical gene KLF2A, whose absence results in heart valve defects [7]. In our
laboratories, as well as elsewhere, in vitro mechanical environments that elicit OSS,
such as Flex-Flow or pulsatile flow, demonstrated clear merits of engineered
extracellular matrix (ECM) collagen production and valvular phenotype derived from
human bone marrow mesenchymal stem cells (HBMSCs) [14, 5, 12]. In particular when
the mechanical conditions were in the physiological range (fluid shear stresses of 4-5
dynes/cm2 and cyclic flexure frequency of 1 Hz), de novo tissue content was further
augmented, with relatively-high presence of genes supporting the cardiovascular
phenotype, including robust KLF2A expression [5]. On the other hand, use of a NPPF
condition adversely impacted KLF2A expression, although other pertinent genes (such
as FZD2) and overall ECM collagen content remained unaffected. Regardless of the
specific mechanical conditions used, the common underlying thread in studies where
tissue construct biological properties were substantially improved in comparison to static
culture, was the exposure of BMSC-derived engineered tissues to OSS. Indeed, we
previously established that OSS plays a critical role in the formation of engineered heart
valve tissues when the magnitude of fluid-induced shear stresses is physiologically
relevant [12]. In this investigation, we wanted to identify the specific value(s) of fluid
oscillations rather than the shear stresses that led to these enhanced properties. He and
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Ku [20] have shown that the fluid oscillations can be quantified using the oscillatory
shear index (OSI) (Eq. 1).
Utilizing physiologically relevant hemodynamic conditions from different vascular
sources, here, we took a computational approach towards determining a range of OSI
that may be important in enhancing gene, cell, and tissue-level properties in TEHVs.
Subsequently the effect of physiologically relevant OSI versus non-physiological OSI,
either too high or too low, was evaluated experimentally in HBMSC culture
experiments.
3.1. Methodology of Specific Aim 1
All simulations in this study were carried out using commercially available software
(ANSYS® Workbench 2016, Ansys Inc., Canonsburg, PA) within a Windows® 7 64-bit
Operating System environment (Microsoft Inc., Redmond, WA). A workstation with
dual processors was used to facilitate an efficient and accurate solution convergence
(Intel Xeon® X5550, 2.66 GHz processor speed, Intel Inc., Santa Clara, CA).
The simulations comprised a geometry depicting a flow-stretch-flexure (FSF)
bioreactor which has been used to conduct several tissue engineering experiments in our
laboratory [25, 5, 6, 12]. The bioreactor chamber consists of a U-shaped flow path, with
a diameter of 13 mm. Recognizing the significance of wall shear stress induction
regarding heart valve tissue development, there have been several cases of flow rate that
have been analyzed in the application to the FSF bioreactor, including static, steadystate, pulsatile square waveform, cyclic flexure, and Flex-Flow cases.
For each physiologically relevant pulsatile flow simulation that was run, a no-slip
boundary condition was assigned to the walls of the bioreactor while a porous fluid
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interface was prescribed to the surfaces of each rectangular-shaped scaffold (n = 3
specimens per flow chamber; specimen dimensions: 17 mm x 6.5 mm x 1 mm). Three
pulsatile flow simulations were conducted; specifically, the inlet pulsatile velocity
boundary conditions from two arteries (pulmonary artery (Fig. 2) and aorta (Fig. 3))
[Lotz et al. 2002] and one vein (superior vena cava (Fig. 4)) [36] were used. A zeropressure boundary condition was prescribed at the outlets. All simulations utilized fluid
material properties of basal cell culture media consisting of a density of 1.01 g/cm3 and a
dynamic viscosity of 1.27 cP [6]. Solution convergence was interpreted to have
occurred when residuals arising from the continuity and momentum equations were able
to meet a prescribed convergence criterion of 1 x 10-9.
3.1.1. Inlet and Outlet Boundary Conditions
For the following simulations, three physiological boundary conditions [36] were
separately prescribed across the bioreactor inlet while a zero-pressure boundary
condition was prescribed to the outlet.
3.1.1.1. Pulmonary Arterial Waveform

Figure 2: Pulmonary arterial waveform with peak velocity at 0.095 m/s and a mean velocity at
0.022 m/s
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3.1.1.2. Aortic Waveform

Figure 3: Aortic waveform with peak velocity at 0.109 m/s and a mean velocity at 0.0241 m/s.

3.1.1.3. Superior Vena Caval Waveform

Figure 4: Superior vena caval waveform with peak velocity at 0.025 m/s and a mean velocity at 0.0081
m/s.
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3.1.2. Numerical Independence
Independence testing was carried out to optimize the computational conditions as
follows:
3.1.2.1. Mesh Independence
A bioreactor geometry mesh that we had previously utilized for computational
investigations [6] was used as the basis for the current study (Fig. 5). The optimized
quadrilateral meshing density for the geometry consisted of 441,000 elements and
472,000 nodes. Use of this mesh in a steady flow simulation in comparison to our
previous work [13] yielded a mean specimen wall shear stress (n = 3 specimens) that
was within a 5% margin of agreement.

Figure 5: The FSF bioreactor quadrilateral mesh as shown from both the xz-axis (a) and the yz-axis
(b). The mesh density of the geometry was optimized at 4.72x105 nodes and 4.41x105 elements with
the mesh refined around the samples of the bioreactor, as depicted from the xz-axis (c) and the xy-axis
(d) with the black arrow pointing to the proximal wall of each respective sample and the purple arrow
pointing to the distal wall.

3.1.2.2. Timestep Independence
The pulmonary artery computational fluid dynamics (CFD) simulation was used as the
basis to select a valid time-step for all simulation cases. A time-step of 1 ms yielded a
low Courant number (< 1.00) suggesting that it would permit temporal accuracy in
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resolving the flow computations. However, to facilitate efficiency in computation times
for solution convergence, the time-step was gradually increased (2 ms and 3 ms) to
determine if a solution was possible to within 5% error of the solution derived from the
1-ms time-step case. Eventually, a 2-ms time-step was chosen based on its resulting
time-averaged specimen shear stress prediction (n = 3 specimens), which was found to
be within 5 % of the value obtained for the 1 ms time step simulation.
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Figure 6: Velocity waveforms (a) that produced corresponding shear stress profiles (b) to obtain a (i)
physiologically relevant OSI (OSI = 0.23) (ii) low-OSI (OSI = 0.10) and (iii) high-OSI (OSI = 0.38).
Both (i) and (ii) show velocity waveforms and shear stress profiles at magnified scales, as indicated by
black arrows.

3.1.2.3. Cyclic Independence
In the pulmonary artery CFD simulation the time-averaged specimen wall shear
stresses (n =3) of the 1st and 2nd cycles were compared to their corresponding value in
the 3rd cycle. Both the 1st and 2nd cycles yielded values that were within 1% of the
time-averaged specimen shear stress value obtained from the 3rd cycle. Therefore, all
results presented in this study were taken from the 2nd cycle.
3.1.3. CFD Validation
Results in the current study from the pulmonary artery pulsatile flow simulation
utilizing a structured, quadrilateral mesh were compared to a previously well-established
pulsatile flow simulation from our laboratory which used a tetrahedral, unstructured
mesh [13]. Again, the computed time-averaged specimen wall shear stress metric was
used as the basis for the comparison. The time-averaged specimen shear stress from the
structured mesh was found to be within 5% of the value from the unstructured mesh.
3.1.4 Mechanobiological Testing
First, additional FSF bioreactor simulations were performed using a set of
prescribed velocity waveforms (Fig. 6a) which produced time-averaged shear stress
profiles (Fig. 6b) that were subsequently used to compute three OSI-values representing
low (OSI = 0.10), high (OSI = 0.38) and the sweet-spot (OSI = 0.23) ranges. The
physiologically relevant and high OSI were obtained from the distal wall of the
specimen and low OSI from the proximal wall.
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Next, in cell culture experiments, ~ 1 million HBMSCs (Fisher Scientific, Pittsburgh,
PA) were cultured up to passage 4 (P4). Cells between P4-P6 were subsequently utilized
and plated in bovine-derived fibronectin (Sigma Aldrich St. Louis, MO) coated
microfluidic channels and were subjected to three different OSI groups using a
commercially-available shear stress cell assay system available in our laboratory
(Fluxion Biosciences, South San Francisco, CA; Martinez et al. 2012). HBMSCs were
subjected to a 48-hour conditioning cycle and were subsequently processed for RNA
isolation. A fourth group, a “No flow” or HBMSCs grown in static culture conditions,
was used as a control. Each group comprised of 4 samples, where each sample was
pooled from 2 microfluidic channels.

Table 1: Quantitative real-time polymerase chain reaction primer sequences for gene expression analysis of
HBMSCs.

3.1.5. Gene Expression Analysis
After 48-hours of conditioning, HBMSCs were subjected to gene expression
assessment. In brief, total RNA was isolated according to manufacturer’s protocol
(RNeasy Micro kit, Qiagen) and was quantified using NanoDrop 2000c
spectrophotometer (Thermo Fisher Scientific, Pittsburgh, PA). 200ng of total RNA was
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used for the cDNA synthesis RevertAid First Strand cDNA Synthesis kit (Thermo
Fisher, Waltham, CA). The primers (Table 1) were designed using Primer3 software and
gene sequences were obtained from Basic Local Alignment Search Tool (BLAST)
program, National Center for Biotechnology Information (NCBI). Quantitative real-time
polymerase chain reaction (qRT-PCR) was performed using a commercially available
kit Maxima SYBER Green/ROX qPCR Master Mix (Thermo Fisher Scientific,
Pittsburgh, PA). Signals were detected with the Step-One Real-Time PCR System
(Applied Biosystems). The change in cycle threshold (Ct) values were averaged and
normalized with GAPDH, an endogenous gene using the Ct method [Schmittgen and
Livak 2008]. Untreated HBMSCs were used as a control for data analysis.
3.1.6. Statistical Analysis
Shear stress and OSI findings on housed-bioreactor specimens (n=3) were presented as
the mean ± standard error of the mean (SEM). An ANOVA analysis was performed for
the 5 groups compared, namely, the three physiologically relevant pulsatile flow cases
conducted here, and from the previously performed Flex-Flow [5] and NPPF
[12]studies. A Tukey’s post hoc test was conducted followed by a one-way ANOVA to
assess any significance between the groups (SPSS, V16, IBM, Armonk, NY). A
statistically significant difference between groups was determined to have occurred
when p < 0.05.
3.2. Results of Specific Aim 1
3.2.1. Velocity Streamlines
Velocity contours were taken from cross-sectional planes of the bioreactor across the
proximal and distal walls of the scaffolds (fig. 7-9). In verifying of proper coupling of
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the profile to the inlet of the bioreactor, the contours of the planes for each time point
follow in accordance with the acceleratory and deceleratory phases of the waveform for
each profile case. The bottom plane, where the distal walls are taken into account, has a
notably higher velocity distribution than the top plane of each profile case.

3.2.1.2. Pulmonary Artery

Figure 7: Instantaneous velocity contours of the pulmonary arterial profile under five
equitemporal time points from both the top plane (proximal walls) and the bottom plane (distal
walls). Peak velocity is distinguished at the peak of the waveform at 0.16 s.
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3.2.1.2. Aorta

Figure 8: Instantaneous velocity contours of the aortic profile under five equitemporal time points
from both the top plane (proximal walls) and the bottom plane (distal walls). Peak velocity is
distinguished at the peak of the waveform at 0.16 s.
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3.2.1.3. Superior Vena Cava

Figure 9: Instantaneous velocity contours of the superior vena caval profile under five
equitemporal time points from both the top plane (proximal walls) and the bottom plane (distal
walls). Peak velocity is distinguished at the peak of the waveform at 0.12 s.

3.2.2. Vorticity Plots
Vortices and eddy currents were quantified on cross-sectional contour planes
intersecting across the middle of the second scaffold within the bioreactor (Fig. 10-12).
Trends in high magnitude vortices were observed notably around the scaffold juncture of
the contour maps for each profile case analyzed with peak magnitude vorticity densities
occurring during the deceleratory phase of each profile case, when flow reversal would
start to manifest.
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3.2.2.1. Pulmonary Artery

Figure 10: Sample-intersecting vorticity contour maps of the pulmonary arterial profile at seven
time points.
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3.2.2.2. Aorta

Figure 11: Sample-intersecting vorticity contour maps of the aortic profile at seven time points.

28

3.2.2.3. Superior Vena Cava

Figure 12: Sample-intersecting vorticity contour maps of the superior vena caval profile at seven
time points.

3.2.3. Instantaneous Axial Wall Shear Stress Approximations
The spatial distributions of shear stresses were presented for both the distal and
proximal walls of the bioreactor specimens at the specific time points of the cardiac
cycle (Fig. 13-15). The cardiac cycle durations for the pulmonary artery, aortic, and
superior vena cava were 1.08 s, 1.05 s and 1.08 s respectively [Lotz et al. 2002]. In all
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simulations carried out, maximum specimen shear stresses corresponded with the peak
temporal position of the prescribed pulsatile velocity profile as expected. Also in
general, shear stresses were higher on the distal side of the specimens as compared to the
proximal side.
3.2.3.1. Pulmonary Artery
In the pulmonary artery case, during the early acceleration phase (t = 1.08 s) of the
cardiac cycle, the resulting shear stresses were not uniformly distributed (Fig. 13).
However sufficient inertial forces at a time instance (t = 1.12 s) proximal to the peak
velocity temporal position enabled higher shear, streamlined laminar flow. During the
latter stages of flow deceleration, reversal of flow was observed (at t = 1.36s).
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Figure 13: Instantaneous sample shear stress contours for pulmonary arterial simulation. For time
points 0.00 s, 0.04 s, 0.08 s, 0.16 s, 0.24 s, 0.28 s and 0.32 s, the shear stress averages were 0.08 ±
0.002, 0.46 ± 0.009, 1.8 ± 0.02, 2.5 ± 0.02, 1.3 ± 0.01, 0.76 ± 0.009 and 0.28 ± 0.007,
respectively.

3.2.3.2 Aorta
The aortic velocity waveform-derived specimen shear stress distributions evolved
similarly to the pulmonary artery case (Fig. 14). However, the aortic shear stresses
increased in magnitude more rapidly, reaching a maximum value at t =1.20 s as opposed
to the pulmonary artery simulation (t = 1.24 s); similarly, noticeable flow deceleration
effects on specimen shear stress were occurred sooner in the aorta (at t =1.32 s
comparing Fig 3a to 3b).
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Figure 14: Instantaneous sample shear stress contours for aortic simulation. For time points 0.00
s, 0.04 s, 0.08 s, 0.16 s, 0.24 s, 0.28 s and 0.32 s, the shear stress averages were 0.21 ± 0.003, 0.59
± 0.006, 2.0 ± 0.02, 2.7 ± 0.02, 1.2 ± 0.01, 0.49 ± 0.009, and -0.06± 0.008, respectively.

3.2.3.3. Superior Vena Cava
As would be expected, the bulk specimen shear stress ranges were considerably lower
in venous flow conditions (Fig. 15) as opposed to arteries (Fig. 13 and 14). Multiple
temporal positions at and beyond the mid-point of the deceleration phase (t =1.36 s)
revealed substantial flow disturbances as well as flow reversal from the principal flow
direction.
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Figure 15: Instantaneous sample shear stress contours for superior vena cava simulation. For time
points 0.04 s, 0.08 s, 0.12 s, 0.20 s, 0.28 s, 0.32 s, and 0.36 s, the shear stress averages were 0.024
± 0.0003, 0.043 ± 0.0004, 0.057 ± 0.0004, 0.047 ± 0.0003, 0.017 ± 0.0002, 0.004 ± 0.0002, and 0.003 ± 0.0002 respectively.

3.2.4. Oscillatory Shear Stresses
OSI distributions for both the proximal and distal walls were plotted (Fig. 16) for all
three CFD simulation cases of physiologically relevant pulsatile flow and compared to
our previous findings utilizing a non-physiological square waveform [12] and a
combination of physiological-scales of cyclic flexure (1 Hz) and steady flow (FlexFlow; flow rate of 850 ml/min) [5, 6]. The overall OSI (Mean ± SEM) for the entire
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specimen (n =3; i.e., considering both proximal and distal sides) for the pulmonary
arterial, aortic, superior vena cava, square pulsatile, and Flex-Flow conditions were as
follows: 0.23 ± 0.002, 0.18 ± 0.002, 0.19 ± 0.001, 0.37 ± 0.021, and 0.1055 ± 0.052,
respectively. Therefore, the range of OSI was found to be: 0.18 ≤ OSI ≤ 0.23 across the
three physiological pulsatile flow waveforms investigated. This range was found to be
significantly lower and higher to non-physiological and non-pulsatile flow-induced OSI
(Flex-Flow) cases respectively (p < 0.05).

Figure 16: OSI contours (n=3) of the samples housed within the FSF bioreactor. The mean OSI of
the distal walls for the pulmonary arterial, aortic, superior vena cava, square wave, and Flex-Flow
conditions were 0.28 ± 0.002, 0.25 ± 0.002, 0.27 ± 0.001, 0.45 ± 0.023, and 0.117± 0.003,
respectively. On the other hand, the corresponding mean OSIs for the proximal wall were as
follows: 0.18 ± 0.002, 0.10 ± 0.002, 0.11 ± 0.001, 0.29 ± 0.019, and 0.094± 0.10, respectively.
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3.2.5. Analysis of Gene Expression
A significantly higher expression (p<0.05) of valve developmental genes KLF2A and
BMP2, as well as significantly greater up-regulation (p < 0.05) of endothelial and
activated interstitial markers CD31 and α-SMA respectively, were found in the
physiologically relevant “sweet-spot” OSI samples in comparison to the low and high
OSI groups (Fig. 17a). On the other hand, the expression of the bone or calcification
marker, osteocalcin was statistically insignificant (p > 0.05) between the three groups
(Fig 17b).
NOTCH1, a valve development gene, was significantly down-regulated (p < 0.05) in
the low OSI group as compared to the high OSI and physiologically relevant “sweetspot” OSI groups, which were both modestly up-regulated (Fig 17c). In addition, there
was significant down-regulation of TGFb1 (associated with valve calcification) in the
low and “sweet-spot” OSI groups (p < 0.05) in comparison to their high OSI
counterpart, which was upregulated. Finally, no statistically significant differences (p >
0.05) were observed in the VCAM1 expression, a known inflammatory marker (Fig.
17a).
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Figure 17: Gene expression following 48 hours of HBMSCs exposed to low OSI (OSI = 0.10), high
OSI (OSI = 0.38), and physiologically relevant “sweet-spot” OSI (OSI = 0.23). Error bars are displayed
as ± SEM; (n=4 samples/group). (a) A statistically significant (p < 0.05) expression of CD31, -SMA
was found in the physiologically relevant OSI-treated group as compared to the low and high OSI
counterparts. (b) A significantly higher expression (p < 0.05) of BMP2 was also observed in the
physiologically relevant OSI groups as compared to the other two groups. No significant differences (p
> 0.05) were found to occur in the expression of osteocalcin between the groups. (c) KLF2A and
NOTCH1 genes exhibited a significantly higher expression (p < 0.05) in the physiologically relevant
OSI group. Finally, TGFb1 was significantly down-regulated in the low OSI and physiologically
relevant groups (p < 0.05) in comparison to high OSI-treatment wherein it was upregulated.

3.3. Discussion of Specific Aim 1
Bioreactor-based mechanical conditioning experiments have shown that Flex-Flow
conditions and square pulsatile conditions lead to enhanced matrix development and
valve phenotype compared to either steady state flow or cyclic flexure alone [14, 5, 12].
Coupling of cyclic flexure and steady flow conditions augments regional specimen
oscillatory shear stresses. Studies have demonstrated the critical link between oscillatory
shear stress and valve development, whose absence leads to down-regulation of key
valvular genes, such as KLF2A, thereby resulting in heart valve defects [7]. The
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mechanisms of gene regulation are not fully delineated; however, it has already been
shown that oscillatory flow-induced stimulus activates mechanosensitive ion channels
which lead to gene expression critical in valvulogenesis [37]. This indicates that the
localized condition surrounding the valve that necessitates development requires an
oscillatory flow component. Specifically, OSS-mediated cell stimulation of KLF2A
occurs via the trpv4 and trpp2 calcium channels [37]. We have since shown that the OSI
can be used as a single metric that co-relates with benefits in specimen properties
observed from stem cell-derived heart valve tissue engineering experiments [6];
Moreover, oscillatory shear stress environments can be mediated through pulsatile flowalone without the need for flexing specimens [13]. In the present investigation, we
hypothesized that healthy valve tissues are exposed to a distinct range of OSI, which
may be important in maintaining homeostasis, i.e., an OSI “sweet-spot”.
Work we conducted previously using square pulsatile conditions [12] within the same
flow-stretch-flexure bioreactor exhibited an OSI of 0.29 ± 0.019 on the proximal wall
and an OSI of 0.45 ± 0.023 on the distal wall surface (Fig. 16), with an overall specimen
OSI average of 0.37 ± 0.021. This indicated significantly higher (p < 0.05) oscillatory
shear stresses compared to OSI derived from physiological flow profiles, which was in
the order of 0.18 to 0.23. In addition, this range of OSI was determined across 3 distinct
blood vessel flow profiles (pulmonary artery, aorta and superior vena cava).
The context of this narrow OSI range (0.18 ≤ OSI ≤ 0.23) is important given that
higher oscillatory shear stresses fail to promote upregulation of key valvular genes
(again, such as KLF2A), although this does not appear to alter collagen concentration in
in-vitro grown engineered tissues [5]. We speculate that phenotype is highly regulated
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by the specific oscillatory shear stress environment (and likely ideal when within the
OSI “sweet-spot” range), whereas the ECM content may not as drastically effected by
OSI magnitude. To obtain direct evidence of mechanical conditioning effects on
HBMSCs using a “sweet-spot” value of OSI, we were subsequently able to demonstrate
experimentally that an OSI = 0.23 led to maximum expression (relative to lower (OSI =
0.10) and higher OSI (OSI = 0.38) values; Fig. 17) of the valve developmental genes
BMP2 and KLF2A. The context of this narrow OSI is important given that higher
oscillatory shear stresses failed to promote up-regulation of key valvular genes. KLF2a,
an athero-protective transcription factor, is released by endothelial cells, thereby
preventing abnormal ECM due to inflammation during valve morphogenesis [37, 7].
BMP2 is involved during the very early stages of myocardial development and is
involved in several vital functions during endocardial cushion formation, including
ECM synthesis and tissue growth as well as initial mesenchymal cell proliferation and
differentiation to promote the valvular phenotype [38–40]. Moreover, exposure of
HBMSCs to the sweet-spot OSI range (OSI = 0.23) led to significant (p< 0.05) upregulation of phenotypic markers CD31 (endothelial) and α-SMA (interstitial) indicative
of enhanced HBMSC differential capacity in vitro as compared to corresponding
exposure to relatively lower (OSI = 0.10) and higher (OSI = 0.38) OSI values.
Collectively, the primary biological significance of the “sweet-spot” OSI identified here
is to enhance in vitro gene expression and phenotype in HBMSC-based heart valve
tissue engineering using a clearly quantified narrow range of OSI values as opposed to
utilizing a random selection of oscillatory flow magnitudes.
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Conversely, Flex-Flow conditions (1 Hz cyclic flexure combined with steady flow
spatial mean specimen shear stress of 5 dynes/cm2) previously resulted in a distal OSI
of 0.117 ± 0.003, a proximal OSI of 0.094± 0.10 and an overall specimen OSI of 0.106
± 0.052 [5]. While both the cyclic flexure and shear stress magnitudes were
physiologically relevant, the net OSI was not since it was significantly smaller (p < 0.05)
than the OSI "sweet-spot" determined here. The biological implications of exposing
engineered valve tissues to physiologically relevant scales of OSI is not entirely clear;
however, incorporation of oscillatory shear stresses has augmented phenotype and ECM
content under previous Flex-Flow conditions [5]. Here, we have found via performing
OSI-based HBMSC experiments, that this can be further improved if the OSI can be
moved to within the physiological range, i.e., the “sweet-spot” that was identified here.
The bioreactor system which we utilized is able to mimic regionally varying shear
stresses on the specimen surfaces and is analogous to native tri-leaflet heart valve shear
stress distributions [25]. Indeed, the range of OSI (0.18 – 0.23) identified here is closeto the typical OSI experienced by aortic valve tissues (OSI ~ 0.16) [41]. Previous studies
on Flex-Flow conditions by [5] and [6] found that the 3-dimensional coupling of cyclic
flexure, cyclic stretch and fluid-induced shear stresses manifest as oscillatory patterns
surrounding the localized flow field of the heart valve leaflets. The flow patterns act on
the leaflet surface as oscillatory shear stress. Extensive evidence of oscillatory
regulation of valvular gene regulation [7], particularly via Trpv4 and Trpp2 ionic
channels [37], has previously been reported. Thus, from a biomimetic standpoint, we
interpret that the similarity in values we identified in the current study to the OSI of
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native, healthy human aortic valves which maintains valve homeostasis, will enhance
engineered valve tissue development and phenotype.
This study has several limitations and assumptions. We only simulated the biofluid
dynamics within 3 vascular locations. Moreover, we did not consider the movement of
the heart valve leaflets which is likely to alter specific OSI magnitudes. There are some
limitations associated with our bioreactor-derived OSI values from CFD; firstly, the FSF
bioreactor that we used for the CFD portion of the current study has been shown to
recapitulate the flow patterns experienced by the native tri-leaflet aortic valves[42, 25].
Moreover, the averaged OSI across the entire aortic valve surface was previously
reported to be an OSI ~0.16 [41] which is close to the “sweet spot” OSI range (0.180.23) of the current study. However, we note that fluid-induced oscillations are
considerably greater on the fibrosa surface as compared to the ventricularis surface and
as a result, regional OSI can vary. The “sweet-spot” OSI range reported here and
derived from FSF bioreactor CFD simulations, as well as the native aortic valve,
represents averaged values for all surfaces and some differences between bioreactor
versus native valve-OSI are bound to occur (~ 25%) and thus represents another
limitation of this study. Finally, we speculate that the biological responses of cells other
than HBMSCs to the OSI “sweet-spot” or physiologically relevant window of OSI (0.18
≤ OSI ≤ 0.23) may not be the same. Moreover, experiments reported herein were
performed in monolayer culture and as a result, the extent to which cell-ECM, i.e. 3dimensional, interactions would be regulated by the “sweet-spot” OSI identified here is
not known. Nonetheless the current investigation does serve to demonstrate the relative
distinctions between physiologically-induced OSI versus non-physiological counterparts
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and established that the physiological range needed to promote valvular gene expression
and HBMSC differentiation towards the valvular phenotype is narrow. In addition, a
specific OSI for stem-cell derived tissue engineering experiments using pulsatile flow
mechanical conditioning was quantified here using a series of CFD simulations.
Moreover, use of an OSI value (OSI = 0.23) taken from the sweet-spot OSI range (0.18
≤ OSI ≤ 0.23) resulted in preferential valvular gene expression and phenotype in
HBMSC culture experiments that were conducted in the current study. Thus, the OSI
“sweet-spot” can now serve as a target for construct optimization for functional heart
valve repair and/or replacement regenerative therapies.

4. SPECIFIC AIM 2

Aortic valve calcification is a predominant cause for aortic insufficiency [43, 18,
40]. While there are surgical treatment options available, they have distinct limitations
and are generally performed when the native valve is already beyond repair.
Additionally, pharmacological management of calcific valve disease during early stages
is currently unavailable. Therapeutic discoveries in the treatment of early stages of
aortic valve calcification requires a fundamental understanding of cellular mechanisms
that are regulated by both the local biochemical and biomechanical environments and
have been the subject of extensive research.

From a biomechanics standpoint, fluid-induced shear stresses across the leaflets have
been closely linked to normal and pathological valve tissue remodeling activity [41, 14,
8, 10, 17, 16, 44], but specific shear stress patterns and magnitudes both spatial and
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temporal have not yet been strongly linked to the underlying cell autocrine and paracrine
signaling events that regulate the valve extracellular matrix (ECM). Nonetheless, the
incidence of low shear, disturbed laminar flow resulting in temporal blood flow
oscillatory patterns on the fibrosa side of aortic valve leaflets has been shown to strongly
correlate to regions of calcific nodule deposition and aggregation [10, 17]. The resulting
oscillatory shear stresses (OSS) have thus been implicated in valve pathology [41, 45].
We have previously shown that OSS promotes the formation of engineered heart valve
tissues [5, 6, 12]. Collectively, the common theme in valve tissue engineering and
calcification in the context of OSS is its association with active tissue remodeling
activity. However, the distinction between these scenarios may ultimately lie in the
specific magnitude of oscillations that trigger the synthesis of healthy versus
pathological valve ECM. Even less understood is the regional changes in fibrosa OSS
that occur with aging.

As a first step in elucidating connections between OSS and calcification on the
aortic valve surfaces, here, we took a computational approach to determine changes in
OSS patterns on the human aortic valve fibrosa before and after calcific nodule
deposition. We subsequently compared these findings to regions of the fibrosa that did
not develop any pathology.

4.1. Methodology for Specific Aim 2

All simulations in this study were carried out using commercially available software
(ANSYS® Workbench 2016, Ansys Inc., Canonsburg, PA) within a Windows® 7 64-bit
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Operating System environment (Microsoft Inc., Redmond, WA). A workstation with
dual processors was used to facilitate an efficient and accurate solution convergence
(Intel Xeon® X5550, 2.66 GHz processor speed, Intel Inc., Santa Clara, CA).

Computed tomography (CT) reconstructions of a human aortic valve with and without
severe calcification (Fig. 18a, b) were obtained (82-year old female; Valve-012 HeartPrint catalog, Materialise Inc., Plymount MI). The temporal position of the valve
structure depicted the early-diastolic phase wherein the leaflets would be in the process
of closing. The valve geometry without calcific nodules (fig. 18c) was first discretized
utilizing a tetrahedral mesh density (1.70x103 nodes and 7.73x103 elements, fig. 18e).
Calcified nodules were then placed as spatially determined from CT images to the
healthy valve geometry (fig. 18d); as before, a tetrahedral mesh (4.89x104 nodes,
2.63x105 elements, fig. 18f) was subsequently generated for the calcified valve.

The fluid was modelled as blood, using a viscosity and density of 3.5 centipoise and
1.06 g/cm3, respectively. A no-slip boundary condition was applied to the entire
geometry for each valve model. Pulsatile flow simulations were run for the healthy and
diseased aortic valve with solution convergence interpreted to have occurred when
residuals arising from the continuity and momentum equations were able to meet a
convergence criterion of 1 x 10-9.
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Figure 18: (a) Healthy aortic valve Fibrosa geometry in early diastole, with left coronary cusp (LCC),
right coronary cusp (RCC) and non-coronary cusp (NCC), before and (b) after calcification. (c)The
simulated healthy valve fibrosa model and (d) its corresponding mesh, had calcified nodules (black)
added across the leaflets for (e) the diseased valve model and (f) its corresponding mesh. Areas of
interest (A1, A2, A3, A4) on those regions represented both calcified areas (A3) and unaffected areas of
the diseased valve (A4) and the areas corresponding to the calcified regions (A1) and unaffected regions
(A2) on the healthy valve. (h) On the diseased valve, calcified deposits were analyzed both
independently and as a collective zone (area A3, black) [A3-NCC (126 mm2, located at distal belly of
NCC), A3-RCC (117.2 mm2, located at tips and proximal belly of RCC) and A3-LCC (51.9 mm2,
located at proximal belly of LCC)] along with the regions surrounding the deposits (area A4, red) [A4NCC: 194.3 mm2; A4-RCC: 203.6 mm2; A4-LCC: 240 mm2] within each specific cusp. (g) The deposit
regions corresponding to the diseased valve were then analyzed across the healthy valve (area A1,
black) [A1-NCC: 144.93 mm2; A1-RCC: 81.08 mm2; A1-LCC:17.07 mm2] along with the areas
consistent with the regions surrounding the deposits (area A2, red) [A2-NCC: 151.26 mm2; A2-RCC:
218.16 mm2; A2-LCC:291.24 mm2].
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4.1.1. Inlet and Outlet Boundary Conditions

An aortic waveform used in our previous aim and originally described by Lotz et al.
[36] was prescribed to the inlet while an 80 mm Hg-pressure boundary condition was
prescribed to the outlet.

4.1.2. Numerical Independence

Independence testing on both valve geometries was carried out to optimize the
computational conditions as follows:

4.1.2.1. Mesh Independence

For the healthy valve geometry, an initial, fine tetrahedral mesh density
of 6.67x104 nodes and 3.62x105 elements was used. After running through a steady state
simulation of 30 iterations, an optimized tetrahedral mesh density of 1.70x103 nodes
and 7.73x103 elements was determined after finding the averaged wall shear stress of the
valve and surrounding anatomy was within 5% of the initial fine mesh. Subsequently,
the

diseased

valve

was

assigned

an

initial, fine

tetrahedral mesh

density

of 1.21x105 nodes and 6.69x105 elements. An optimized tetrahedral mesh density
of 4.89x104 nodes and 2.63x105 elements was determined, using a steady state
simulation of 30 iterations, to find the averaged wall shear stress of the valve and
surrounding anatomy, similarly was within 5% of its initial, fine mesh valve.
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4.1.2.2. CFL-timestep selection and subsequent CFD model validation

For both valve geometries utilized,

the

Courant-Friedrichs-Lewy condition

was

satisfied with a Courant number <1 for a timestep of 1 ms [46]. In addition, with the 80
mm Hg outlet condition satisfied, both healthy and diseased valve geometries exhibited
a computed average inlet pressure of within 5% of a physiologically realistic value of
120 mm Hg.

4.1.2.3. Cyclic Independence

Three cycles were prescribed to the inlet of each valve geometry. The healthy valve
model had an error of 2% between the 1st and 3rd cycles and 1.7% between the 2nd and
3rd cycle. The diseased valve had an error of 14.9% between the 1st and 3rd cycle
and 1.7% between the 2nd and 3rd cycle. Ultimately, the 3rd cycle was selected for
analysis in the healthy valve model and the diseased valve model.

4.2. Results of Specific Aim 2

4.2.1. Time-Averaged Shear Stress

The spatial distributions of axial time-averaged wall shear stresses (TAWSS) were
presented on the healthy valve (Fig. 19a) and diseased valve (Fig. 19c).

4.2.1.1. Healthy Valve Model

The ventricularis side of the valve (fig. 20a) had an average (± SEM) axial shear stress
of 1.25 ± 0.0195 dynes/cm2. As expected, the distribution of the shear stresses on the
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fibrosa side was relatively low in magnitude. The maximum axial shear stresses on the
valve were concentrated at the leaflet tips while minimum, negative shear stresses were

Figure 19: Healthy Valve spatial distribution of axial time-averaged wall shear stresses (a,
mean: 0.091 dynes/cm2) and OSI (b, mean: 0.0998). Calcified Valve spatial distribution of
axial time-averaged wall shear stresses (c, mean: 0.323 dynes/cm2) and OSI (d, mean: 0.1557).
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Fig. 20: Healthy ventricularis geometry plots of (a) axial time-averaged wall shear stress
(TAWSS) (mean: 1.25 dynes/cm2) and (b) OSI (mean: 0.003457) as well as diseased
ventricularis geometry plots for (c) axial TAWSS (mean: 1.95 dynes/cm2) and (d) OSI
(mean: 0.01)

predominantly located across the fibrosa LCC. The mean fibrosa axial stress value of the
valve was 0.091± 0.067 dynes/cm2.

4.2.1.2. Calcified Valve Model

The ventricularis side of the valve (fig. 20c) exhibited an average axial shear stress
average (± SEM) of 1.95 ± 0.001 dynes/cm2. Maximum shear stresses were, as in the
case of the healthy valve, located at the leaflet tips. Minimum, negative stresses were
concentrated at the surface of the LCC (fig. 19c). The average fibrosa axial shear stress
value of the valve was 0.32 ± 0.004 dynes/cm2.
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4.2.2. Oscillatory Shear Index

The spatial distributions of OSI were computed for the healthy valve (Fig. 19b) and
diseased valve (Fig. 19d) cases; averaged OSI values were subsequently summarized
(Table 3, Table 4). OSI of Cusp-designated regions A1 – A4 (Fig. 18g-18h) were also
reported (Table 3) with the following observations:

4.2.2.1. Healthy Valve Model

OSI on the ventricularis side of the valve was negligible (fig. 20b, mean OSI = 0.004).
On the other hand, on the fibrosa side, the OSI was relatively much higher on the RCC
(OSI = 0.147) while the NCC had an averaged OSI of 0.060 and the LCC had an OSI of
0.027. The OSI average of the entire fibrosa side was computed to be OSI = 0.103.

4.2.2.2. Calcified Valve Model

Similar to the healthy valve, the OSI on the ventricularis side of the valve was
substantially lower than that of the fibrosa (fig. 20d, mean OSI =0.010). The OSI field
across the LCC (plaque area: 5.23%; mean OSI =0.211; Table 2) had a distinct, nonuniform distribution with high OSI regions surrounding the calcified deposit on its
surface (fig. 19d). Additionally, the RCC (plaque area: 39.8%) and the NCC (plaque
area: 38.2%) exhibited a mean OSI of 0.131 and 0.051, respectively. The OSI of the
entire fibrosa side was computed to be 0.156.
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4.2.2.3. Regions that developed calcification

Regions that developed calcification, A3 on the NCC, RCC and LCC, had mean OSIs
of 0.06, 0.101, and 0.108 respectively with the collective OSI of these regions (area A3,
Fig. 18h) exhibiting an overall Mean ± SEM OSI: 0.089 ± 0.015. The corresponding
regions of A3 on the healthy valve were 0.009, 0.232, and 0.023 with the mean OSI of
these regions (area A1, Fig. 18g): 0.088 ± 0.0721. The unaffected regions surrounding
A3 on the NCC, RCC and LCC had OSIs of 0.0267, 0.1522, and 0.2411, respectively,
with the mean OSI of these regions (area A4, Fig. 18h): 0.14 ± 0.0622. Corresponding
regions for A4 on the healthy valve had OSIs of 0.05, 0.215, and 0.044 with a mean OSI
of these regions (area A2, Fig. 18g): 0.103 ± 0.056.

4.2.3. %Change in OSI

The percent decrease in OSI (Table 4) in the region of the calcified valve (A3)
compared to the same location when it was not diseased (A1) was found to be marginal
(1.59%). On the other hand, the regions that remained unaffected by calcification on
both valves (A2, A4) had a much more substantial decrease in OSI by 35. 9%.
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Aortic Valve Side

Healthy OSI

Diseased OSI

Plaque
Percentage

Ventricularis

0.0035

0.01

0%

NCC

0.0603

0.0393

38.2%

LCC

0.0268

0.2114

5.23%

RCC

0.1472

0.1310

39.8%

Table 2: Healthy and diseased OSI on both ventricularis and fibrosa sides of valve with percent of
calcified plaque occupying each cusp. Particularly, there was a significant change in OSI between the
diseased and healthy LCC (p < 0.05).

Calcified Region

A1

A2

A3

A4

NCC

0.009

0.05

0.0597

0.0267

LCC

0.232

0.215

0.1009

0.1522

RCC

0.023

0.044

0.1077

0.2411

Mean± SEM

0.088 ± 0.0721

0.103 ± 0.056

0.0894 ± 0.015

0.14 ±
0.0622

Table 3: OSI on cusp-designated areas of valve fibrosa (A1-A4) for each region. Note that A3 and
A4 are the calcified regions and unaffected regions of the calcified valve, respectively, while A1 and
A2 are the corresponding calcified regions and corresponding unaffected regions on the healthy
valve. Mean ± SEM is provided for each area. A slight shift in OSI (1.6%) occurred between the
means of A1 and A3.

%Change
(Mean A1 &
Mean A3)

%Change
(Mean A2 &
Mean A4)

%Change of
mean OSI in
NCC

%Change of
mean OSI in
RCC

%Change
of mean
OSI in
LCC

1.59 (SD: 1.12,
SEM:0.80)

35.9 (SD: 25.4,
SEM:18)

34.8

11.0

688.0

Table 4: Percent (%) change in mean OSI of cusp-designated regions and in mean OSI across distinct
valvular cusps. There was a markedly low percent change between the means of A1 and A3 (1.6 %)
compared to the change between the means of A2 and A4 (36%).
9
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4.3. Discussion of Specific Aim 2

Axial TAWSS results from both affected and unaffected regions of both valve
models (Fig. 19a, 19c) revealed non-unidirectional flow existed across the fibrosa,
demonstrating that the native valve environments could produce OSS. The computed
shear stresses of the aortic valve model simulated here had values [-5.94 dynes/cm2 54.7 dynes/cm2] within the ranges previously reported in the literature [11, 30, 17, 16]
with relatively lower shear stresses found on the fibrosa side (mean: 0.091 dynes/cm2)
compared to the ventricularis side of each model (mean:1.25 dynes/cm2).

The aortic valve OSI environment shifted remarkably between healthy and diseased
valve physiologies.

Consistent with previous work [48, 47, 17], our findings

demonstrated that the NCC and RCC were the most susceptible to calcification. The
healthy valve OSI for the NCC (OSI mean: 0.060), RCC (mean: 0.131) and LCC (mean:
0.027) established that OSI across a healthy valve geometry could vary between the
three aortic valve leaflets; the diseased valve OSI of the NCC (OSI mean: 0.039), RCC
(mean: 0.147) and LCC (mean: 0.211) similarly also varied. These findings suggest that
relative changes in OSI or lack thereof between healthy and valve pathologies could
potentially be used to predict regions on the valve fibrosa prone to calcification.
Specifically, we speculate that in situations where the rate of valve matrix remodeling
slows down, a change in OSI is unlikely, in time, making the valve susceptible to
triggering abnormal ECM synthesis. The current study was able to confirm that indeed,
regions susceptible to high calcification had only marginal changes in the OSI (healthy
tissue area, A1: Mean ± SEM: 0.088 ± 0.072 and same tissue area A1, after calcification,

53

i.e., A3: Mean ± SEM: 0.089 ± 0.015), resulting in a % change in OSI of only 1.59%).
Conversely, regions of the aortic valve that did not get calcified, i.e. A2 and later, A4,
exhibited a rather substantial % change in OSI of nearly 36%. We interpret that regional
ECM remodeling of the fibrosa, particularly in the primary ECM components of the
valve, i.e., collagen, glycosaminoglycans, and elastin, alter the valve shape which will
change the OSI as would be expected in the localized leaflet surface environment.
However, when this remodeling does not occur or occurs slower than needed, the OSI
does not change, potentially triggering a disease pathway. In particular, since aortic
valve calcification is strongly correlated with the aging process, it is likely that the slow
turnover of elastin remodeling in the valve may be primarily associated with changes in
OSI that occurs over decades, and leads to pathologies later in life, as recent studies
have similarly suggested [53, 50, 54, 8, 49, 51, 11, 43, 52, 10]

The findings in this brief report are very preliminary and contain two major
limitations in the approaches. Firstly, a single patient’s valve was analyzed before and
after calcification. Secondly, the flow physics in a pulsatile flow model without
accounting for valve leaflet motion was simulated during the early-diastolic, closing
phase of the valve. While the absolute OSI values would be very different from those
uncovered here, the general trend that negligible longitudinal changes in OSI co-relate
with a higher probability of disease due to insufficient valve ECM remodeling, is likely
to hold. Thus, in conclusion, we present in these short communications, a new
interpretation of OSI in the context of valve tissue remodeling. In cases of tissue
regeneration, a set value of OSI may be targeted to promote de novo tissue growth in-
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vitro as we previously described in aim 1. However, when the OSI remains relatively
unchanged in the native aortic valve fibrosa environment, this may be suggestive of an
absence of or insufficient valve ECM remodeling, which could lead to a triggering point
for valve pathologies. Therefore, in addition to the OSI environment, a change in the
longitudinal and regional leaflet, fibrosa-side OSI conditions with aging, or lack thereof
may serve useful as a bio-marker (e.g. a % change in OSI computed every 5 years after
the age of 40) for the early detection of aortic valve calcification.

5. CONCLUSION
Through utilization of a computational approach, the results included in this thesis
have demonstrated the application and significance of oscillatory flow, namely OSS,
within heart valve tissue engineering and heart valve disease. Specifically, these results
have shown that physiologically relevant OSI environments can produce an optimized
phenotype for BMSC-derived engineered valve tissue. Pulsatile conditions that produce
an OSI within the “sweet spot” range (0.18≤ OSI≤ 0.23) can now be used in bioreactor
designs for proper conditioning of TEHVs. Furthermore, results have additionally
established the method of using changes in OSI in detecting aortic valve remodeling that
predispose native valve tissue towards higher probabilities of leaflet calcification.
Current efforts are focused on in-vitro experiments that will provide quantifiable data to
further support our findings.
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